FindMyKOL
Clinical trialNCT02574611WithdrawnPhase 1Interventional

Use of High Resolution Colonic Manometry in Studying Motility

NCT02574611 is a phase 1 interventional trial sponsored by James J. Peters Veterans Affairs Medical Center. As of 21 Nov 2026, it was withdrawn. It studies Glycopyrronium and Neostigmine in Gastrointestinal Dysfunction. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 13 Oct 2015 and a primary completion date of 25 Dec 2017.

SponsorJames J. Peters Veterans Affairs Medical CenterEnrollment0Gastrointestinal Dysfunction
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT02574611
FieldValue
Registry IDNCT02574611
StatusWithdrawn
PhasePhase 1
Study typeInterventional trial
Lead sponsorJames J. Peters Veterans Affairs Medical Center
Enrollment0
Registered sites1
Countries1
ConditionsGastrointestinal Dysfunction
DrugsGlycopyrronium and Neostigmine
Start13 Oct 2015
Primary completion25 Dec 2017
Study completion25 Dec 2018
Last update posted28 Sept 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

An injury to the spinal cord (SCI) results in numerous medical complications, including gastrointestinal (GI) function. Individuals with SCI may experience severe constipation (prolonged stool retention), incontinence (accidents), and overall difficulty in bowel evacuation. While various treatments and medications have been established to address this complication, there is little knowledge relating to the overall colonic motility. However, new technology such as High Resolution Colonic Manometry allows physicians to visualize high pressure contractions inside the colon, leading to a greater understanding of typical motility, a more accurate diagnosis, and an effective treatment. In this study, the investigators propose to use this technology to understand the effects of SCI on colonic motility by comparing to normal colonic function observed in able-bodied (AB) individuals. In addition, the investigators plan to study the effects of pharmacological treatments, such as neostigmine, on promoting peristaltic contractions in the colon as it is delivered across the skin.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • James J. Peters Va Medical Center

    The Bronx

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT02574611

Each answer restates registry values shown on this page.

What is NCT02574611?

NCT02574611 is a phase 1 interventional trial sponsored by James J. Peters Veterans Affairs Medical Center. It studies Glycopyrronium and Neostigmine in Gastrointestinal Dysfunction.

Who leads NCT02574611?

The registry names Mark Korsten, MD (principal investigator, James J. Peters Veterans Affairs Medical Center) as the overall official.

Where does NCT02574611 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT02574611 study?

The registered drug and biological interventions are Glycopyrronium and Neostigmine.

When did NCT02574611 end?

The registry lists a primary completion date of 25 Dec 2017 and a study completion date of 25 Dec 2018. The sponsor last updated the record on 28 Sept 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.